Navigation Links
Publishers John Wiley & Sons Enter Into An Agreement With NASPGHAN And AASLD

Global publisher John Wiley & Sons, Inc., confirms their plans to go into a partnership with NASPGHAN and AASLD for providing subscriptions of their journal.//

International publisher John Wiley & Sons, Inc., had announced on the 6th of September their plans of a new agreement with the North American Society for Paediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) and the American Association for the Study of Liver Diseases (AASLD).

Announcing that under this agreement they would provide complimentary subscriptions of the journal Hepatology to all NASPGHAN fellows, they explained that Wiley & Co publishes ‘Hepatology’, which is the official journal of AASLD on behalf of the Association. The journal is one of the leading worldwide journals that publish original, peer-reviewed articles pertaining to all aspects of liver, its structure, function, and disease.

“As chair of the AASLD Publications Committee, I am pleased that our publisher, John Wiley & Sons, Inc. is providing Hepatology without charge to trainees in Paediatric Gastroenterology/Hepatology,” said William Balistreri, M.D. “Hepatology is the premier journal in the field and access to the important basic and translational research published in its pages will stimulate young investigators and we hope lead to the improved care of children with hepatobiliary disease.”

"NASPGHAN welcomes this partnership with AASLD and Wiley and appreciates the generous support extended to the training and educating of our next generation of paediatric gastroenterologist," said Philip M. Sherman, M.D., and President of NASPGHAN.

Source-EurekalertVIK
'"/>




Page: 1

Related medicine news :

1. More Doctors Suspended As Strike Enters Seventh Day
2. Doctors Strike In Andhra Enters The Second Day
3. Anti-Quota Stir: Stalemate Continues; Fast Enters 10th Day
4. Bird Flu Virus Entered New Zealand
5. AIIMS Strike Enters Second day, Support Continues To Pour In
6. JIPMER Strike Enters Eighth Day
7. Enbrelr Enters Safer Zone After Recent Research
8. Most Of The Ear Infections Entertain Both Bacteria And Viruses
9. The Food Pyramid Guide Enters Supermarkets
10. Pharma Major Ind-Swift to Enter US, Japan
11. Vandetanib Study Enters Third Phase
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... ... Usually, the impending arrival of warmer weather means the gleeful banishment of ... chin, this means more anxiety than elation. The cosmetic dermatology experts at Cosmetic Laser ... chin is undesirable,” Dr. Goldman said, “but it seems doubly so when the fat ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... release of two biometric time and attendance tracking products: the new NCheck Cloud ... NCheck Cloud Bio Attendance uses biometric face recognition to enable users to check ...
(Date:3/28/2017)... ... ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics in Ohio and New ... sit on the 2017 National Advisory Board for Allergan’s Facial Aesthetics National Advisory Board., ... the clinic from a small start-up to number 78 in the country based on ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Lice ... Atlantic City March 13-16, was a busy spot this year. Liz Solovay and ... strategies for preventing outbreaks among camp communities during the upcoming 2017 camping season. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Nurse practitioners ... as their value increases in the healthcare workforce, according to a survey recently ... boards, career fairs, and candidate leads to healthcare employers of physicians and advanced ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Israel , March 28, 2017 Emosis ... This new business entity, Emosis Ltd, headquartered in Tel ... of novel assays complementing the mother company existing technology platform and ... and sales development of Emosis kits. ... This strategic move starts building Emosis international footprint. ...
(Date:3/28/2017)... 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a ... commercialization of innovative therapies for the treatment of ... Agency (EMA) has notified the company that the ... Application (MAA) has passed validation, and that the ... MAA for ARX-04 (known as DSUVIA™ in the ...
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
Breaking Medicine Technology: